2016 Hematological Malignancies

• Brentuximab Vedotin (anti-CD30 ADC) • AFM13 (CD16/CD30 bispecific) • Lenalidomide (IMID) • Everolimus, (mTor-inhibitor) • Rituximab, Ofatumumab (anti-CD20) • Panobinostat, Mocitinostat (H-DAC inhibitors) • TKI´s, JAK2i, PARPi • PD-1 inhibitors New Antibodies and Molecules in Hodgkin Lymphoma